Intima Bioscience

Intima Bioscience is a clinical-stage company based in New York, United States. According to its website, it focuses on a next-generation small molecule checkpoint inhibitor targeting CISH, described as a novel immune checkpoint. The company states it has conducted a clinical trial at the University of Minnesota Masonic Cancer Center, employing CRISPR genetically engineered CISH-knockout T-cells as a model system to evaluate the safety and efficacy of this classically undruggable intracellular target. The trial is listed on ClinicalTrials.gov under ID NCT04426669 and is described as a study of metastatic gastrointestinal cancers treated with tumor infiltrating lymphocytes in which the gene encoding the intracellular immune checkpoint CISH is inhibited using CRISPR genetic engineering.

Intima Bioscience is a clinical-stage company based in New York, United States. Its website states that it focuses on a next-generation small molecule checkpoint inhibitor targeting CISH, described as a novel immune checkpoint. The company states it has conducted a clinical trial at the University of Minnesota Masonic Cancer Center, employing CRISPR genetically engineered CISH-knockout T-cells as a model system to evaluate the safety and efficacy of this classically undruggable intracellular target. The trial is registered on ClinicalTrials.gov under ID NCT04426669 and is described as a study of metastatic gastrointestinal cancers treated with tumor infiltrating lymphocytes in which the gene encoding the intracellular immune checkpoint CISH is inhibited using CRISPR genetic engineering. The company's news section lists a February 11, 2026 item that Dr. Emil Lou, Intima Bioscience Principal Investigator, was named to the 2026 TIME100 Health List, and a May 1, 2025 item on data from a first-in-human trial targeting CISH in patients with metastatic colorectal cancer.

A clinical-stage company focused on a next-generation small molecule checkpoint inhibitor CISH.

• Small molecule checkpoint inhibitor targeting CISH

  A next-generation small molecule checkpoint inhibitor targeting CISH, described as a novel immune checkpoint.

• CRISPR genetically engineered CISH-knockout T-cells

  Used as a model system in a clinical trial to evaluate the safety and efficacy of the classically undruggable intracellular target CISH.

1. 1Intima Bioscienceintimabioscience.com
2. 2Intima Bioscience (United States)wikidata.org